Global Transdermal Drug Delivery System Market Research Report 2025

Publication ID:

PB505253540

Publication Date:

May 13, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Transdermal Drug Delivery System was valued at US$ 19300 million in the year 2024 and is projected to reach a revised size of US$ 45700 million by 2031, growing at a CAGR of 13.3% during the forecast period.
Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.
In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.
This report aims to provide a comprehensive presentation of the global market for Transdermal Drug Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Drug Delivery System.
The Transdermal Drug Delivery System market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Transdermal Drug Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transdermal Drug Delivery System companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
Segment by Type
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Segment by Application
OTC
Rx
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transdermal Drug Delivery System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transdermal Drug Delivery System Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Fentanyl
1.2.3 Nitroglycerin
1.2.4 Estradiol
1.2.5 Nicotine
1.2.6 Other
1.3 Market by Application
1.3.1 Global Transdermal Drug Delivery System Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 OTC
1.3.3 Rx
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transdermal Drug Delivery System Market Perspective (2020-2031)
2.2 Global Transdermal Drug Delivery System Growth Trends by Region
2.2.1 Global Transdermal Drug Delivery System Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Transdermal Drug Delivery System Historic Market Size by Region (2020-2025)
2.2.3 Transdermal Drug Delivery System Forecasted Market Size by Region (2026-2031)
2.3 Transdermal Drug Delivery System Market Dynamics
2.3.1 Transdermal Drug Delivery System Industry Trends
2.3.2 Transdermal Drug Delivery System Market Drivers
2.3.3 Transdermal Drug Delivery System Market Challenges
2.3.4 Transdermal Drug Delivery System Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transdermal Drug Delivery System Players by Revenue
3.1.1 Global Top Transdermal Drug Delivery System Players by Revenue (2020-2025)
3.1.2 Global Transdermal Drug Delivery System Revenue Market Share by Players (2020-2025)
3.2 Global Transdermal Drug Delivery System Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Transdermal Drug Delivery System Revenue
3.4 Global Transdermal Drug Delivery System Market Concentration Ratio
3.4.1 Global Transdermal Drug Delivery System Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transdermal Drug Delivery System Revenue in 2024
3.5 Global Key Players of Transdermal Drug Delivery System Head office and Area Served
3.6 Global Key Players of Transdermal Drug Delivery System, Product and Application
3.7 Global Key Players of Transdermal Drug Delivery System, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Transdermal Drug Delivery System Breakdown Data by Type
4.1 Global Transdermal Drug Delivery System Historic Market Size by Type (2020-2025)
4.2 Global Transdermal Drug Delivery System Forecasted Market Size by Type (2026-2031)
5 Transdermal Drug Delivery System Breakdown Data by Application
5.1 Global Transdermal Drug Delivery System Historic Market Size by Application (2020-2025)
5.2 Global Transdermal Drug Delivery System Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Transdermal Drug Delivery System Market Size (2020-2031)
6.2 North America Transdermal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Transdermal Drug Delivery System Market Size by Country (2020-2025)
6.4 North America Transdermal Drug Delivery System Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transdermal Drug Delivery System Market Size (2020-2031)
7.2 Europe Transdermal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Transdermal Drug Delivery System Market Size by Country (2020-2025)
7.4 Europe Transdermal Drug Delivery System Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transdermal Drug Delivery System Market Size (2020-2031)
8.2 Asia-Pacific Transdermal Drug Delivery System Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Transdermal Drug Delivery System Market Size by Region (2020-2025)
8.4 Asia-Pacific Transdermal Drug Delivery System Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transdermal Drug Delivery System Market Size (2020-2031)
9.2 Latin America Transdermal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Transdermal Drug Delivery System Market Size by Country (2020-2025)
9.4 Latin America Transdermal Drug Delivery System Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transdermal Drug Delivery System Market Size (2020-2031)
10.2 Middle East & Africa Transdermal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Transdermal Drug Delivery System Market Size by Country (2020-2025)
10.4 Middle East & Africa Transdermal Drug Delivery System Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Hisamitsu
11.1.1 Hisamitsu Company Details
11.1.2 Hisamitsu Business Overview
11.1.3 Hisamitsu Transdermal Drug Delivery System Introduction
11.1.4 Hisamitsu Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.1.5 Hisamitsu Recent Development
11.2 Mylan
11.2.1 Mylan Company Details
11.2.2 Mylan Business Overview
11.2.3 Mylan Transdermal Drug Delivery System Introduction
11.2.4 Mylan Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.2.5 Mylan Recent Development
11.3 GSK
11.3.1 GSK Company Details
11.3.2 GSK Business Overview
11.3.3 GSK Transdermal Drug Delivery System Introduction
11.3.4 GSK Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.3.5 GSK Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Transdermal Drug Delivery System Introduction
11.4.4 Novartis Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Teve (Actavis)
11.5.1 Teve (Actavis) Company Details
11.5.2 Teve (Actavis) Business Overview
11.5.3 Teve (Actavis) Transdermal Drug Delivery System Introduction
11.5.4 Teve (Actavis) Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.5.5 Teve (Actavis) Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Transdermal Drug Delivery System Introduction
11.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 Lohmann
11.7.1 Lohmann Company Details
11.7.2 Lohmann Business Overview
11.7.3 Lohmann Transdermal Drug Delivery System Introduction
11.7.4 Lohmann Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.7.5 Lohmann Recent Development
11.8 Teikoku Seiyaku
11.8.1 Teikoku Seiyaku Company Details
11.8.2 Teikoku Seiyaku Business Overview
11.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Introduction
11.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.8.5 Teikoku Seiyaku Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Transdermal Drug Delivery System Introduction
11.9.4 Bayer Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.9.5 Bayer Recent Development
11.10 Lingrui
11.10.1 Lingrui Company Details
11.10.2 Lingrui Business Overview
11.10.3 Lingrui Transdermal Drug Delivery System Introduction
11.10.4 Lingrui Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.10.5 Lingrui Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Transdermal Drug Delivery System Introduction
11.11.4 Sanofi Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.11.5 Sanofi Recent Development
11.12 Qizheng
11.12.1 Qizheng Company Details
11.12.2 Qizheng Business Overview
11.12.3 Qizheng Transdermal Drug Delivery System Introduction
11.12.4 Qizheng Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.12.5 Qizheng Recent Development
11.13 Endo
11.13.1 Endo Company Details
11.13.2 Endo Business Overview
11.13.3 Endo Transdermal Drug Delivery System Introduction
11.13.4 Endo Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.13.5 Endo Recent Development
11.14 Huarun 999
11.14.1 Huarun 999 Company Details
11.14.2 Huarun 999 Business Overview
11.14.3 Huarun 999 Transdermal Drug Delivery System Introduction
11.14.4 Huarun 999 Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.14.5 Huarun 999 Recent Development
11.15 Haw Par
11.15.1 Haw Par Company Details
11.15.2 Haw Par Business Overview
11.15.3 Haw Par Transdermal Drug Delivery System Introduction
11.15.4 Haw Par Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.15.5 Haw Par Recent Development
11.16 Nichiban
11.16.1 Nichiban Company Details
11.16.2 Nichiban Business Overview
11.16.3 Nichiban Transdermal Drug Delivery System Introduction
11.16.4 Nichiban Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.16.5 Nichiban Recent Development
11.17 Mentholatum
11.17.1 Mentholatum Company Details
11.17.2 Mentholatum Business Overview
11.17.3 Mentholatum Transdermal Drug Delivery System Introduction
11.17.4 Mentholatum Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.17.5 Mentholatum Recent Development
11.18 Laboratoires Genevrier
11.18.1 Laboratoires Genevrier Company Details
11.18.2 Laboratoires Genevrier Business Overview
11.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Introduction
11.18.4 Laboratoires Genevrier Revenue in Transdermal Drug Delivery System Business (2020-2025)
11.18.5 Laboratoires Genevrier Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂